The pharmaceutical and medical device industries face mounting pressure in 2026, with stricter infection control standards and a surge in demand for complex, single-use devices. In response, Medistri, Europe’s leading independent sterilization provider, has launched its second ethylene oxide (EO) sterilization line in Hungary. This $2.5 million, 18-month project aims to meet growing client needs and strengthen supply chain resilience.
A strategic move for a growing market
EO sterilization remains the go-to method for heat and moisture-sensitive devices, holding 48.1% of the global market. The sterilization services sector itself is expanding rapidly, projected to grow from $6.37 billion in 2026 to $10.64 billion by 2034, driven by tighter regulations and increased outsourcing.
For Medistri, the new Hungarian line not only boosts capacity but also reinforces its role as a key partner for healthcare innovators, from startups to big pharma companies. “It’s a pleasure to deliver this capacity for our Eastern European customers, a true team effort,” says Shoko Nilforoushan, Medistri’s founder and general manager.
Founded in 2006, Medistri has built its reputation on integrated services (sterilization, lab testing, packaging validation, and manufacturing) that allow clients to focus on their core business while ensuring compliance and safety. This expansion aligns with broader industry trends: automation, digital monitoring, and a push for sustainability, as EO sterilization faces environmental and regulatory scrutiny.
As the demand for safer, more efficient sterilization solutions continues to rise, how will companies like Medistri balance innovation, sustainability, and regulatory compliance in the years ahead?